Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK2036874A vaccine · 1 trial · 6 indications
Seroprotection was defined as anti-polio types 1, 2 and 3 antibody titres ≥ 8 effective dose (ED50), for 50% of vaccinated subjects.
Antibody titers were presented as geometric mean titers (GMTs).
| Arm | Type | Description |
|---|---|---|
| GSK2036874A GROUP 1 | EXPERIMENTAL | Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0. |
| GSK2036874A GROUP 2 | EXPERIMENTAL | Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0. |
| GSK2036874A GROUP 3 | EXPERIMENTAL | Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0. |
| ZILBRIX/HIB/POLIORIX GROUP | ACTIVE_COMPARATOR | Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib™ and Poliorix™ vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively. |
| Name | Type | Description |
|---|---|---|
| GSK2036874A vaccine | BIOLOGICAL | Intramuscular, single dose |
| Zilbrix™/Hib vaccine | BIOLOGICAL | Intramuscular, single dose |
| Poliorix™ | BIOLOGICAL | Intramuscular, single dose |
Inclusion Criteria: * A male or female subject, between and including 12 and 24 months of age at the time of booster vaccination. * Subjects who have received three doses of polio vaccine as primary vaccination along with the routine vaccinations indicated during the first year of life. * Subjects ...
GSK2036874A vaccine is an investigational vaccine being studied for Haemophilus Influenzae Type b, a bacterial infection that can cause serious illness in children. It is also being evaluated in combination with vaccines for tetanus, hepatitis B, whole cell pertussis, diphtheria, and poliomyelitis.
GSK2036874A vaccine is being developed by GSK plc, a global biopharma company traded on the London Stock Exchange under the ticker GSK. The company is conducting clinical research on this vaccine candidate for Haemophilus Influenzae Type b.
GSK2036874A vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the vaccine remains under clinical investigation.
GSK2036874A vaccine has one completed Phase 2 clinical trial, NCT01106092, which evaluated the immunogenicity and reactogenicity of a booster dose in healthy toddlers. The trial enrolled 312 participants in the Philippines and was randomized, double-blind, and active-controlled.
GSK2036874A vaccine is a monoclonal antibody designed to target Haemophilus Influenzae Type b. As a vaccine, it is intended to stimulate an immune response against this bacterial pathogen, potentially providing protection against infection.